https://glutathione-signal.com..../index.php/ultrafast
Analysis of the results revealed that MSC-released IL-6 promotes tumor invasion and metastasis, activating the JAK-STAT3 signaling. A potential treatment for enhancing the prognosis and survival rate of OSCC patients lies in tocilizumab's blockage of this crucial pathway. The results pointed to a mechanism where MSC-released IL-6 enhanced tumor invasion and metastasis through the JAK-STAT3 signaling cascade. By inhib
پسندیدن
اظهار نظر
اشتراک گذاری
